Javier Pena-Perez

Albacete, CM, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: February 20, 2020

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin.

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin.

Journal: Nutrients
Published: April 15, 2019

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Journal: Oncoimmunology
Published: March 23, 2019

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Journal: PloS one
Published: November 27, 2018

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.

Journal: Journal of cellular and molecular medicine
Published: October 28, 2018

Mapping Bromodomains in breast cancer and association with clinical outcome.

Mapping Bromodomains in breast cancer and association with clinical outcome.

Journal: Scientific reports
Published: September 19, 2018

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Journal: Breast cancer research and treatment
Published: July 16, 2018

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Journal: Scientific reports
Published: June 12, 2017

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Journal: Oncotarget
Published: October 19, 2016

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Journal: Oncotarget
Published: June 20, 2016

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Journal: Oncotarget
Published: May 23, 2016

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Journal: Molecular cancer therapeutics
Published: January 20, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026